BriaCell Therapeutics Corp.
BCT.TO
TSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.55M | 6.39M | 6.31M | 6.36M | 6.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.37M | 27.20M | 24.42M | 27.32M | 29.98M |
| Operating Income | -30.37M | -27.20M | -24.42M | -27.32M | -29.98M |
| Income Before Tax | -29.01M | -26.56M | -19.64M | -11.72M | -16.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.01 | -26.56 | -19.64 | -11.72 | -16.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 297.90K | 244.20K | 206.10K | 131.60K | 124.50K |
| Net Income | -28.71M | -26.31M | -19.43M | -11.59M | -16.60M |
| EBIT | -30.37M | -27.20M | -24.42M | -27.32M | -29.98M |
| EBITDA | -30.27M | -27.10M | -24.27M | -27.19M | -29.87M |
| EPS Basic | -53.28 | -81.60 | -82.57 | -50.06 | -132.76 |
| Normalized Basic EPS | -33.16 | -50.79 | -51.27 | -30.97 | -82.59 |
| EPS Diluted | -53.30 | -81.61 | -82.57 | -50.06 | -132.77 |
| Normalized Diluted EPS | -33.16 | -50.79 | -51.27 | -30.97 | -82.59 |
| Average Basic Shares Outstanding | 3.40M | 1.70M | 940.40K | 673.30K | 509.80K |
| Average Diluted Shares Outstanding | 3.40M | 1.70M | 940.40K | 673.30K | 509.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |